JP2010513320A - ピルフェニドン治療を患者に提供する方法 - Google Patents
ピルフェニドン治療を患者に提供する方法 Download PDFInfo
- Publication number
- JP2010513320A JP2010513320A JP2009541645A JP2009541645A JP2010513320A JP 2010513320 A JP2010513320 A JP 2010513320A JP 2009541645 A JP2009541645 A JP 2009541645A JP 2009541645 A JP2009541645 A JP 2009541645A JP 2010513320 A JP2010513320 A JP 2010513320A
- Authority
- JP
- Japan
- Prior art keywords
- day
- pirfenidone
- dose
- days
- compartments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 title claims abstract description 161
- 229960003073 pirfenidone Drugs 0.000 title claims abstract description 158
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 7
- 239000007858 starting material Substances 0.000 claims abstract description 110
- 238000000034 method Methods 0.000 claims abstract description 48
- 230000002354 daily effect Effects 0.000 claims description 55
- 239000006187 pill Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 229940017668 pirfenidone 267 mg Drugs 0.000 claims description 3
- 230000003203 everyday effect Effects 0.000 claims description 2
- 230000002411 adverse Effects 0.000 abstract description 12
- 239000003814 drug Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 208000032140 Sleepiness Diseases 0.000 description 4
- 206010041349 Somnolence Diseases 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000003176 fibrotic effect Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000006933 Hermanski-Pudlak Syndrome Diseases 0.000 description 2
- 206010071775 Hermansky-Pudlak syndrome Diseases 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000003352 fibrogenic effect Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229940017665 pirfenidone pill Drugs 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- -1 PDGF Proteins 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J2205/00—General identification or selection means
- A61J2205/50—General identification or selection means using icons or symbolic figures, e.g. by a graphical representation symbolising the type of pathology or the organ by an image
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87059306P | 2006-12-18 | 2006-12-18 | |
| PCT/US2007/087988 WO2008077068A1 (en) | 2006-12-18 | 2007-12-18 | Method of providing pirfenidone therapy to a patient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010513320A true JP2010513320A (ja) | 2010-04-30 |
| JP2010513320A5 JP2010513320A5 (cg-RX-API-DMAC7.html) | 2011-02-17 |
Family
ID=39259551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009541645A Pending JP2010513320A (ja) | 2006-12-18 | 2007-12-18 | ピルフェニドン治療を患者に提供する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (9) | US7767700B2 (cg-RX-API-DMAC7.html) |
| EP (4) | EP3053580B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010513320A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE506060T1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2667654C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1111699T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE602007014113D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2124945T3 (cg-RX-API-DMAC7.html) |
| ES (3) | ES2581844T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009006526A (cg-RX-API-DMAC7.html) |
| PL (2) | PL2124945T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2124945E (cg-RX-API-DMAC7.html) |
| SI (1) | SI2124945T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008077068A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014522861A (ja) * | 2011-07-19 | 2014-09-08 | セル セラピー アンド テクノロジー，エス．エー． デーイー シー．ヴィ． | 徐放錠の形態でピルフェニドンを含有する医薬組成物の調製のためのプロセスならびにヒトの慢性腎不全、乳房被膜拘縮および肝線維症の退行におけるその適用 |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008077068A1 (en) | 2006-12-18 | 2008-06-26 | Intermune, Inc. | Method of providing pirfenidone therapy to a patient |
| AU2012205256B2 (en) * | 2008-11-10 | 2015-05-28 | Intermune, Inc. | Pirfenidone Treatment for Patients with Atypical Liver Function |
| US7635707B1 (en) * | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
| US7566729B1 (en) | 2008-11-10 | 2009-07-28 | Intermune, Inc. | Modifying pirfenidone treatment for patients with atypical liver function |
| EP2389227A4 (en) * | 2009-01-26 | 2012-08-08 | Intermune Inc | METHOD FOR THE TREATMENT OF ACUTE MYOCARDINE CARDS AND ASSOCIATED ILLNESSES THEREOF |
| US8084475B2 (en) | 2009-12-04 | 2011-12-27 | Intermune, Inc. | Pirfenidone therapy and inducers of cytochrome P450 |
| US7816383B1 (en) | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
| HUE058753T2 (hu) | 2011-01-31 | 2022-09-28 | Avalyn Pharma Inc | Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik |
| US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| CA2819967C (en) * | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
| HK1220133A1 (zh) | 2013-03-15 | 2017-04-28 | Intermune, Inc. | 改善微血管完整性的方法 |
| USD731783S1 (en) | 2014-04-16 | 2015-06-16 | Abbvie Inc. | Template for a prescription medicine container |
| USD731171S1 (en) | 2013-10-07 | 2015-06-09 | Abbvie Inc. | Template for a prescription medicine container |
| USD731782S1 (en) | 2013-10-07 | 2015-06-16 | Abbvie Inc. | Template for a prescription medicine container |
| AU2015204558B2 (en) | 2014-01-10 | 2020-04-30 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| EP3432879B1 (en) * | 2016-03-22 | 2021-01-06 | Mayo Foundation for Medical Education and Research | Using fatty acid synthase inhibitors to treat fibrosis |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| WO2019028062A1 (en) | 2017-07-31 | 2019-02-07 | Washington University | PIRFENIDONE DERIVATIVES FOR MODULATION OF B-LYMPHOCYTE ACTIVITY AND PROTECTION OF ORGANS |
| US11052021B2 (en) | 2018-03-22 | 2021-07-06 | Abbvie Inc. | Medicine container, method of assembling the container, and method of dispensing the medicine from the container |
| USD930974S1 (en) | 2018-03-22 | 2021-09-21 | Abbvie Inc. | Child-resistant medication container |
| USD930973S1 (en) | 2018-03-22 | 2021-09-21 | Abbvie Inc. | Child-resistant medication container |
| USD882243S1 (en) | 2018-03-26 | 2020-04-28 | Abbvie Inc. | Child-resistant medication container assembly |
| EP3829632A4 (en) * | 2018-07-27 | 2022-05-04 | Société des Produits Nestlé S.A. | Oral immunotherapy unit dose dispensing systems and methods |
| WO2021110805A1 (en) | 2019-12-04 | 2021-06-10 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
| GB2589635B (en) * | 2019-12-06 | 2021-12-01 | Merxin Ltd | Elongate form medicament carrier and medicament dispenser |
| CN117042738A (zh) * | 2021-03-17 | 2023-11-10 | 埃科特莱茵药品有限公司 | 药物剂量系统 |
| WO2023161668A1 (en) | 2022-02-28 | 2023-08-31 | Nuformix Technologies Limited | Compositions and methods for treatment of idiopathic pulmonary fibrosis |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US695044A (en) * | 1901-12-28 | 1902-03-11 | Albert E Gibson | Non-refillable bottle. |
| SE9502370D0 (sv) | 1995-06-30 | 1995-06-30 | Astra Ab | Blister pack, especially for drugs, as well as method and device in manufacturing the same |
| US6956044B1 (en) * | 2000-02-21 | 2005-10-18 | Margolin Solomon B | Compositions and methods for treatment of epilepsy |
| ATE452637T1 (de) * | 2001-01-29 | 2010-01-15 | Shionogi & Co | Arzneipräparat, das als wirkstoff 5-methyl-1- phenyl-2-(1h)-pyridon enthält |
| WO2004019863A2 (en) * | 2002-08-28 | 2004-03-11 | Intermune, Inc. | Combination therapy for treatment of fibrotic disorders |
| US7413749B2 (en) * | 2003-03-11 | 2008-08-19 | Purdue Pharma L.P. | Titration dosing regimen for controlled release tramadol |
| CA2525647A1 (en) * | 2003-05-16 | 2005-02-24 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
| US20070092488A1 (en) * | 2003-05-16 | 2007-04-26 | Intermune Inc. | Methods of treating idiopathic pulmonary fibrosis |
| WO2005000227A2 (en) * | 2003-06-06 | 2005-01-06 | Intermune, Inc. | Methods of treating tnf-mediated disorders |
| US20070053877A1 (en) * | 2003-08-21 | 2007-03-08 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
| US7407973B2 (en) * | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| EP2305697A3 (en) * | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
| NZ591443A (en) | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
| US20070203202A1 (en) * | 2005-12-02 | 2007-08-30 | Robinson Cynthia Y | Methods of reducing adverse events associated with pirfenidone therapy |
| US20080003635A1 (en) * | 2006-06-12 | 2008-01-03 | Intermune, Inc. | High Throughput Collagen Synthesis Assay |
| ATE533486T1 (de) * | 2006-06-15 | 2011-12-15 | Shanghai Genomics Inc | Verwendung von pyridonderivaten zur vorbeugung und behandlung von strahlungsbedingter lungenverletzung |
| RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| WO2008077068A1 (en) | 2006-12-18 | 2008-06-26 | Intermune, Inc. | Method of providing pirfenidone therapy to a patient |
| US20080287508A1 (en) * | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
| WO2008144720A2 (en) * | 2007-05-21 | 2008-11-27 | University Of Washington | Inhibitors of igf-1r signaling for the treatment of respiratory disorders |
-
2007
- 2007-12-18 WO PCT/US2007/087988 patent/WO2008077068A1/en not_active Ceased
- 2007-12-18 ES ES11002040.1T patent/ES2581844T3/es active Active
- 2007-12-18 PL PL07865831T patent/PL2124945T3/pl unknown
- 2007-12-18 SI SI200730641T patent/SI2124945T1/sl unknown
- 2007-12-18 DK DK07865831.7T patent/DK2124945T3/da active
- 2007-12-18 JP JP2009541645A patent/JP2010513320A/ja active Pending
- 2007-12-18 CA CA2667654A patent/CA2667654C/en active Active
- 2007-12-18 EP EP16151564.8A patent/EP3053580B1/en active Active
- 2007-12-18 PL PL16151564T patent/PL3053580T3/pl unknown
- 2007-12-18 ES ES16151564T patent/ES2882956T3/es active Active
- 2007-12-18 DE DE602007014113T patent/DE602007014113D1/de active Active
- 2007-12-18 MX MX2009006526A patent/MX2009006526A/es active IP Right Grant
- 2007-12-18 EP EP11002040.1A patent/EP2338489B1/en not_active Revoked
- 2007-12-18 ES ES07865831T patent/ES2395396T3/es active Active
- 2007-12-18 AT AT07865831T patent/ATE506060T1/de active
- 2007-12-18 EP EP07865831A patent/EP2124945B1/en active Active
- 2007-12-18 US US11/959,338 patent/US7767700B2/en active Active
- 2007-12-18 PT PT07865831T patent/PT2124945E/pt unknown
- 2007-12-18 EP EP12150201A patent/EP2471534A1/en not_active Withdrawn
-
2009
- 2009-04-21 US US12/427,532 patent/US7696236B2/en active Active
-
2010
- 2010-07-07 US US12/831,944 patent/US8420674B2/en active Active
-
2011
- 2011-07-12 CY CY20111100674T patent/CY1111699T1/el unknown
-
2013
- 2013-04-11 US US13/861,099 patent/US20130220871A1/en not_active Abandoned
-
2016
- 2016-07-18 US US15/212,674 patent/US20160324842A1/en not_active Abandoned
-
2018
- 2018-01-18 US US15/874,590 patent/US20180140588A1/en not_active Abandoned
- 2018-09-07 US US16/125,299 patent/US20190000821A1/en not_active Abandoned
-
2019
- 2019-04-24 US US16/393,532 patent/US20190247380A1/en not_active Abandoned
- 2019-12-06 US US16/706,575 patent/US20200113884A1/en not_active Abandoned
Non-Patent Citations (4)
| Title |
|---|
| JPN5010002020; ＢＡＢＯＶＩＣ-ＶＵＫＳＡＮＯＶＩＣ Ｄ: ＮＥＵＲＯＬＯＧＹ Ｖ６７ Ｎ１０, 20061128, Ｐ１８６０-１８６２ * |
| JPN5010002021; ＡＺＵＭＡ ＡＲＡＴＡ: ＡＭＥＲＩＣＡＮ ＪＯＵＲＮＡＬ ＯＦ ＲＥＳＰＩＲＡＴＯＲＹ ＡＮＤ ＣＲＩＴＩＣＡＬ ＣＡＲＥ ＭＥＤＩＣＩＮＥ Ｖ１７１ Ｎ９, 20050501, Ｐ１０４０-１０４７ * |
| JPN5010002022; ＢＯＷＥＮ ＪＡＭＥＳ Ｄ: ＭＵＬＴＩＰＬＥ ＳＣＬＥＲＯＳＩＳ Ｖ９ Ｎ３, 200306, Ｐ２８０-２８３ * |
| JPN7013001036; ＲＡＧＨＵ，Ｇ． ｅｔ ａｌ: 'Ｔｒｅａｔｍｅｎｔ ｏｆ ｉｄｉｏｐａｔｈｉｃ ｐｕｌｍｏｎａｒｙ ｆｉｂｒｏｓｉｓ ｗｉｔｈ ａ ｎｅｗ ａｎｔｉｆｉｂｒｏｔｉｃ ａｇｅｎｔ， ｐｉｒｆｅｎｉｄｏｎｅ： ｒｅｓｕｌｔｓ ｏｆ ａ' Ａｍ Ｊ Ｒｅｓｐｉｒ Ｃｒｉｔ Ｃａｒｅ Ｍｅｄ Ｖｏｌ．１５９， Ｎｏ．４ Ｐｔ １, 1999, ｐ．１０６１-９ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014522861A (ja) * | 2011-07-19 | 2014-09-08 | セル セラピー アンド テクノロジー，エス．エー． デーイー シー．ヴィ． | 徐放錠の形態でピルフェニドンを含有する医薬組成物の調製のためのプロセスならびにヒトの慢性腎不全、乳房被膜拘縮および肝線維症の退行におけるその適用 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010513320A (ja) | ピルフェニドン治療を患者に提供する方法 | |
| JP2010513320A5 (cg-RX-API-DMAC7.html) | ||
| TWI618536B (zh) | 於納曲酮療法中增加藥物生物可利用性 | |
| JP2011526866A (ja) | 錠剤用のブリスター包装及び方法 | |
| JP2014529457A (ja) | 患者コンプライアンス用ブリスターパッケージ | |
| CA2570474A1 (en) | A combination composition comprising paracetamol and ibuprofen | |
| HK1172827A (en) | Method of providing pirfenidone therapy to a patient | |
| HK1227319A1 (en) | Method of providing pirfenidone therapy to a patient | |
| HK1153647B (en) | Method of providing pirfenidone therapy to a patient | |
| HK1133584B (en) | Method of providing pirfenidone therapy to a patient | |
| JP2004210401A (ja) | Ｐｔｐ包装体 | |
| Sadowsky | Transdermal rivastigmine for dementia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101217 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111104 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130318 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20130318 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20130327 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130826 |